A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Study on the Efficacy and Safety of Debio 025 Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients

Trial Profile

A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Study on the Efficacy and Safety of Debio 025 Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Alisporivir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Debiopharm Group
  • Most Recent Events

    • 07 Aug 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 23 Jun 2012 Company added in the association field as reported by EudraCT.
    • 21 Apr 2012 European Clinical Trials Database reports trial status as recruting in France and Spain; planned patient number is 272.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top